Phaeohyphomycosis fungal infections in solid organ transplant recipients: clinical presentation, pathology, and treatment

Schieffelin, John S.; Garcia-Diaz, Julia; Loss, George E.; Beckman, Edwin N.; Keller, Richard A.; Staffeld‐Coit, Catherine; Garces, J.; Pankey, George A.

doi:10.1111/tid.12197

Cited by 76 publications

(89 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The frequency of mucormycosis complicating diabetes mellitus has increased, with the emergence of species such as Apophysomyces elegans [9]. Scedosporium, including more recently designated species [5], phaeohyphomycetes such as Verruconis gallopava (previously Ochroconis gallopava) and the genus Rasamsonia [10][11][12][13][14] have been reported in distinct regions or patient populations. The intrinsic resistance of many non-Aspergillus moulds to marketed antifungal agents is of concern [15].…”

Section: Introductionmentioning

confidence: 98%

Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality

Slavin

Hal

Sorrell

et al. 2015

Clinical Microbiology and Infection

146

143

View full text Add to dashboard Cite

The epidemiology of invasive fungal disease (IFD) due to filamentous fungi other than Aspergillus may be changing. We analysed clinical, microbiological and outcome data in Australian patients to determine the predisposing factors and identify determinants of mortality. Proven and probable non-Aspergillus mould infections (defined according to modified European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria) from 2004 to 2012 were evaluated in a multicentre study. Variables associated with infection and mortality were determined. Of 162 episodes of non-Aspergillus IFD, 145 (89.5%) were proven infections and 17 (10.5%) were probable infections. The pathogens included 29 fungal species/species complexes; mucormycetes (45.7%) and Scedosporium species (33.3%) were most common. The commonest comorbidities were haematological malignancies (HMs) (46.3%) diabetes mellitus (23.5%), and chronic pulmonary disease (16%); antecedent trauma was present in 21% of cases. Twenty-five (15.4%) patients had no immunocompromised status or comorbidity, and were more likely to have acquired infection following major trauma (p <0.01); 61 (37.7%) of cases affected patients without HMs or transplantation. Antifungal therapy was administered to 93.2% of patients (median 68 days, interquartile range 19-275), and adjunctive surgery was performed in 58.6%. The all-cause 90-day mortality was 44.4%; HMs and intensive-care admission were the strongest predictors of death (both p <0.001). Survival varied by fungal group, with the risk of death being significantly lower in patients with dematiaceous mould infections than in patients with other non-Aspergillus mould infections. Non-Aspergillus IFD affected diverse patient groups, including non-immunocompromised hosts and those outside traditional risk groups; therefore, definitions of IFD in these patients are required. Given the high mortality, increased recognition of infections and accurate identification of the causative agent are required.

show abstract

Section: Introductionmentioning

confidence: 98%

Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality

Slavin

Hal

Sorrell

et al. 2015

Clinical Microbiology and Infection

146

143

View full text Add to dashboard Cite

show abstract

“…2 These fungi are becoming increasing opportunistic pathogens in solid organ transplant patients. 3 The time from transplantation to onset of infection varies from two months to eleven years. These infections are also known to exist in patients of diabetes mellitus and myelodysplastic syndrome.…”

Section: Discussionmentioning

confidence: 99%

A Rare Case of Brain Abscess

Kumar¹,

Thaha²,

Gilvaz³

2016

jemds

View full text Add to dashboard Cite

show abstract

“…In the recent years other fungi emerged as important infections agents, including yeast species such as non-albicans Candida species, Cryptococcus sp., Trichosporon spp., and Rhodotorula spp. and filamentous fungi such as Fusarium spp., Rhizopus spp., Rhizomucor spp., and phaeohyphomycosis agents (Sun et al, 2012;Juyal et al, 2013;Kim et al, 2013;Muhammed et al, 2013;Jaın et al, 2014;Schieffelin et al, 2014).…”

Section: Fungus: Overall Look In the Main Topicmentioning

confidence: 99%

Mycoses and Antifungals: reviewing the basis of a current problem that still is a biotechnological target for marine products

et al. 2014

View full text Add to dashboard Cite

Currently, the limited number of antifungals available for treating fungal infections, the increased multiresistance, and the adverse effects are the major obstacles for fungal infection therapy. Additionally, the recent emergence of opportunistic fungus infections reinforced the requirement for discovering novel antifungal agents. Herein we reviewed the main topics about fungi and its related infections, the antifungals available, their mechanism of action and resistance profile. In this work, we pointed fungi as a biotechnological target for finding new options in alternative sources such as marine products with new mechanisms of action to allow treating these dangerous infections.

show abstract

Phaeohyphomycosis fungal infections in solid organ transplant recipients: clinical presentation, pathology, and treatment

Abstract: As the number of SOTR increases, so does the incidence of fungal infections in that population. Surgery, along with antifungal therapy and a reduction in immunosuppression, are the cornerstones of treatment.

Cited by 76 publications

References 49 publications

Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality

Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality

A Rare Case of Brain Abscess

Mycoses and Antifungals: reviewing the basis of a current problem that still is a biotechnological target for marine products

Contact Info

Product

Resources

About